Latest news with #Sylvester
Yahoo
7 days ago
- General
- Yahoo
Raceland man accused of attempted murder of kids after setting ‘intentional fire'
RACELAND, La. (WGNO) — A Raceland man is in police custody and facing attempted murder charges following an intentionally set fire. The Louisiana Office of State Fire Marshals Office reported that at 4 p.m. on Wednesday, May 28, 32-year-old Demarcus Sylvester allegedly set fire to the side door of a home in the 200 block of Williams Street. Kenner Police make third arrest in connection to drugging death of news reporter According to deputies, inside the home were a 15-year-old girl and 3-year-old boy. The children were able to escape unharmed and the fire reportedly caused minimal damage. Sylvester was arrested and booked into the Lafourche Parish Correctional Complex on two counts of attempted second degree murder and a count of aggravated arson. Deputies said the investigation remains ongoing. Anyone with information on the incident can call the arson hotline at Miller on report of Musk drug use: We're worried about drugs crossing the border Raceland man accused of attempted murder of kids after setting 'intentional fire' Labor Department suspends Job Corps centers operations, drawing bipartisan pushback State Department restructuring scraps office dedicated to relocating Afghan allies Ernst responds to jeers on Medicaid cuts: 'Well, we're all going to die' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
27-05-2025
- Business
- Yahoo
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Company's positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. The discussion will follow Dr. Theodore DeWeese's* oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The call will also feature insights from leading prostate cancer specialists, John E. Sylvester, M.D., Atlantic Urology Clinics, Myrtle Beach, South Carolina, and Ronald F. Tutrone, Jr., M.D., FACS, CPI, National Medical Director of Clinical Research, United Urology Group, Towson, Maryland. Both physicians were principal investigators on the phase 3 clinical trial. Dr. Sylvester is a renowned prostate cancer specialist with over two decades of experience in radiation oncology. He is widely recognized for his expertise in prostate brachytherapy and advanced radiation treatment techniques. Dr. Sylvester has played a pivotal role in pioneering innovative approaches to prostate cancer care and has authored numerous peer-reviewed publications in the field. He has trained physicians globally and continues to contribute to advancing clinical best practices. His leadership and dedication have earned him a reputation as a trusted authority in prostate cancer treatment and a passionate advocate for improving patient outcomes. Dr. Tutrone is a leading urologist specializing in the diagnosis and treatment of prostate cancer. With over 25 years of clinical experience, he serves as Medical Director of Chesapeake Urology Research Associates and has been principal investigator in numerous clinical trials focused on urologic oncology. Dr. Tutrone is recognized for his commitment to advancing prostate cancer care through research, innovation, and patient-centered treatment. He has published extensively in peer-reviewed journals and is frequently invited to speak at national and international conferences. His work has significantly contributed to improving outcomes for men with prostate cancer. Conference Call and Webcast Candel will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The webcast can be accessed here and on the Candel website at under News & Events, in the IR section of the website. Participants may register for the conference call here to receive dial-in numbers and unique PIN to access the call. Joining 10 minutes prior to the start of the event is recommended, although you may register and dial in at any time during the call. An archived webcast will be available on Candel's website for 30 days following the presentation. * Dr. DeWeese has no relationship with Candel, other than serving as the national principal investigator for Candel's phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer. He has never received reimbursements, consulting fees, or any other fees from Candel, and he has no shares of common stock, options to purchase common stock or any other affiliation with Candel. About CAN-2409 CAN-2409 (aglatimagene besadenovec), Candel's most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient's specific tumor and induce an individualized, systemic immune response against the tumor. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several preclinical and clinical settings. More than 1,000 patients have been dosed with CAN-2409 with a favorable tolerability profile to date, supporting the potential for combination with other therapeutic strategies. Currently, Candel is evaluating CAN-2409 in non-small cell lung cancer (NSCLC) and borderline resectable pancreatic adenocarcinoma (PDAC) and has recently completed a successful phase 3 clinical trial in localized prostate cancer. CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of PDAC, for the treatment of stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy, and for the treatment of localized primary prostate cancer. Candel's pivotal phase 3 clinical trial in prostate cancer was conducted under a Special Protocol Assessment (SPA) agreed with the FDA. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC. About Candel Therapeutics Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and HSV gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and recently completed successful phase 2a clinical trials in NSCLC and PDAC, and a pivotal phase 3 clinical trial in localized prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, expectations regarding the submission of the BLA for CAN-2409 in intermediate-to-high-risk localized prostate cancer and expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company's platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact:Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. tjenkins@ Media Contact:Ben ShannonICR Healthcare CandelPR@ in to access your portfolio
Hypebeast
26-05-2025
- Entertainment
- Hypebeast
First Look at the Nigel Sylvester x Air Jordan 1 Low OG "Nitro"
Name:Nigel Sylvester x Air Jordan 1 Low OG 'Nitro'Colorway:Black/Muslin-Varsity RedStyle Code:IB8958-001MSRP:$150 USDRelease Date:August 2, 2025Where to Buy:Nike Another collaboration betweenJordan BrandandNigel Sylvesteris on its way. Heading to the low tops, Sylvester adds his touch to the upcomingAir Jordan 1 Low OG'Nitro,' which is set to hit shelves later this summer. The BMX icon's upcoming collaboration was revealed via Instagram account@SharKickswhich teased the new colorway that sees the silhouette dressed in a black, muslin and varsity red color scheme. Purposeful scuffing hits the premium leather upper, giving it some added details pertaining to the skate and bike culture while the sail colored Swoosh gives it a more vintage aesthetic. The insoles and tongue branding sees Sylvester's 'Bike Air' logo in the red to contrast the white tongue and laces. The Wings logo hits the heel in white and 'Jordan Biking Co. EST. 2017' is seen stamped on the liner. Look out for the pair expected to drop in early August.
Borneo Post
20-05-2025
- Borneo Post
Man jailed for illegally transferring money
The Kota Kinabalu Court Complex. KOTA KINABALU (May 20): A labourer was sentenced to four years' jail by a Sessions Court here on Tuesday for illegally transferring RM10,000 from a woman's account to another woman's account. Judge Amir Shah Amir Hassan imposed the sentence on Sylvester Ak Drem, 25, after the latter pleaded guilty to a charge under Section 424C (2) of the Penal Code. The indictment provides for a jail term of up to 10 years or a fine of up to RM150,000 or both, upon conviction. Sylvester had committed the offence at a bank branch in Tuaran on November 20, 2024. The court heard that the victim had asked assistance from Sylvester, who is her husband's brother-in-law, to withdraw RM200 for an ATM machine, and after that Sylvester had returned back her ATM card and gave RM200 to her. However, a few days later when the victim wanted to withdraw cash, she found that balance in her bank account had decreased. She then applied for her account to be checked and learnt that there was a transaction involving RM10,000 done on the day she asked for help from the accused to withdraw money. Investigation revealed that Sylvester had transferred the money from the victim's account to his mother's bank account which matched CCTV recordings at the bank branch on the incident day. During the proceedings on Tuesday, when the court inquired where was the money, Sylvester answered that he had spent it all. In his decision, the judge explained that he had taken into consideration that he did not impose a fine punishment because the facts of the case stated that Sylvester had promised to pay back the money, however until a police report was lodged, he had not paid any. The judge also said that he was made to understand that this was the first case in Sabah. The prosecution had informed that there was no reported case in Sabah since the law was gazetted last year. In pleading for a lenient sentence, the unrepresented Sylvester said that he is married and has a child. In reply, the prosecution pressed for a deterrent sentence to serve as a lesson to Sylvester and to would-be offenders to not committing a similar offence. Earlier, Tuaran district police vhief Superintendent Noraidin Ag Maidin said the accused was arrested around 6.30pm on May 16 following a complaint from the victims. 'Investigations found that on November 20, 2024, the suspect transferred RM10,000 from his in-law's bank account into his mother's bank account without their knowledge or consent. 'The suspect then withdrew the money using his mother's ATM card which was in his possession without his mother's consent,' said Noraidin. Noraidin said the accused was the first person in Sabah to be charged under this section after it was introduced through an amendment Act 574 and approved by the Malaysian Parliament in July 2024, and came into effect on October 30, 2024. 'Section 424C(2) provides for punishment for individuals involved in transactions using payment instruments or accounts belonging to others at financial institutions without permission. This measure was taken in response to the increase in cases of online fraud and misuse of bank accounts, including cases of mule account holders. 'Police view such cases seriously including any form of misuse of accounts and financial payment instruments, whether involving outside parties or family members. 'Offences such as this are not only illegal, but also undermine trust in family and financial institutions,' he said. Noraidin advised the public to keep their bank information and bank cards safe and never allow third parties to access their bank accounts, including family members or close friends.
Yahoo
01-05-2025
- Entertainment
- Yahoo
Ex-Singapore hotel staff brings family recipes to Malaysia with comforting claypot dishes & homemade ngoh hiang
If you find yourself wandering around the Hua Joo Park area in Kuching, keep your eyes peeled for a delightful new addition to the local food scene — Sylvester's Kitchen, nestled within Shi Ding Ji coffee shop. Freshly opened on 19 Apr 2025, this hawker stall marks the start of a fresh chapter for 61-year-old Sylvester Lim, who returned to Malaysia for good just last year. After nearly 3 decades of working in hotel service in Singapore, Sylvester decided it was finally time to turn his lifelong passion for cooking into something more — and so, Sylvester's Kitchen was born. For those who know him well, this new venture feels like destiny fulfilled. Throughout his years abroad, Sylvester was known among friends for hosting home gatherings with his cooking as the star of the show. Guests would often ask the same question: 'Why are you only serving and not the one cooking?' Sylvester's Kitchen serves up heartwarming, nostalgia-laden dishes that echo the comforts of home. Think sizzling claypot meals arriving straight to your table piping hot. Signature dishes include classic Braised Pork Leg (RM13) and Sesame Oil Chicken (RM10). There are also Curry Chicken (RM12) and Curry Pork Rib (RM13) — all available daily. Other must-tries are his personal favourites: the Stewed Pork (RM12) and hand-rolled Ngoh Hiang (RM10 per roll), made from a cherished recipe passed down by his late mother. Each roll is generously filled with a savoury blend of pork, prawn, onions, and crunchy water chestnuts. And for a tasty side, don't miss the Lady's Finger topped with homemade Sambal Udang Kering (RM8). Perfect for a kick of umami and heat to your palate. There's something undeniably special about food made with love and passion. So, if you're in the mood for soul-soothing flavours and a story behind every bite, head over to Sylvester's Kitchen with your loved ones. SG hawker brands to open in Macau 5-star hotel The post Ex-Singapore hotel staff brings family recipes to Malaysia with comforting claypot dishes & homemade ngoh hiang appeared first on
